Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 142440
Corporate User License Price USD 6000
Corporate User License Price INR 427320
Site License Price USD 4000
Site License Price INR 284880
Request a Quote

Report Title

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H1 2017



Executive Summary

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H1 2017, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline landscape.

Cushing disease is a condition in which the pituitary gland releases too much adrenocorticotropic hormone (ACTH). Symptoms include acne or skin infections, backache, mental changes, such as depression, anxiety, or changes in behavior. Treatment includes surgery and radiation therapy.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 2, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pituitary ACTH Hypersecretion (Cushing Disease)-Overview

Pituitary ACTH Hypersecretion (Cushing Disease)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pituitary ACTH Hypersecretion (Cushing Disease)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pituitary ACTH Hypersecretion (Cushing Disease)-Companies Involved in Therapeutics Development

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Ipsen SA

Millendo Therapeutics Inc

Novartis AG

Pfizer Inc

Strongbridge Biopharma plc

Pituitary ACTH Hypersecretion (Cushing Disease)-Drug Profiles

Antisense RNAi Oligonucleotide to Inhibit Pro-Opiomelanocortin for ATCH-Dependent Cushing syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATR-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIM-23B065-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levoketoconazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPP-482-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

osilodrostat phosphate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seliciclib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Cushing Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Melanocortin Receptor 2 for ACTH-dependent Cushing syndrome and Congenital Adrenal Hyperplasia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pituitary ACTH Hypersecretion (Cushing Disease)-Dormant Projects

Pituitary ACTH Hypersecretion (Cushing Disease)-Discontinued Products

Pituitary ACTH Hypersecretion (Cushing Disease)-Product Development Milestones

Featured News & Press Releases

Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing Disease, a Serious Endocrine Disorder

Feb 23, 2015: Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare Diseases

Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society 97th Annual Meeting & Expo

Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014

Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014

Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014

Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting

Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial

Jul 30, 2012: Cortendo NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing Syndrome

Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Amryt Pharma plc, H1 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Crinetics Pharmaceuticals Inc, H1 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Ipsen SA, H1 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Millendo Therapeutics Inc, H1 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Novartis AG, H1 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Pfizer Inc, H1 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Strongbridge Biopharma plc, H1 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Dormant Projects, H1 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Ipsen SA

Millendo Therapeutics Inc

Novartis AG

Pfizer Inc

Strongbridge Biopharma plc

Pituitary ACTH Hypersecretion (Cushing Disease) Therapeutic Products under Development, Key Players in Pituitary ACTH Hypersecretion (Cushing Disease) Therapeutics, Pituitary ACTH Hypersecretion (Cushing Disease) Pipeline Overview, Pituitary ACTH Hypersecretion (Cushing Disease) Pipeline, Pituitary ACTH Hypersecretion (Cushing Disease) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person